Log In
BCIQ
Print this Print this
 

BTK inhibitors

  Manage Alerts
Collapse Summary General Information
Company AbbVie Inc.
DescriptionBTK inhibitors
Molecular Target Bruton's tyrosine kinase (Btk)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase I
Standard IndicationRheumatoid arthritis (RA)
Indication DetailsTreat rheumatoid arthritis (RA)
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$21,000.0M

0

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

05/26/2015

$21,000.0M

Undisclosed

0

Get a free BioCentury trial today